Steroid hormone receptors in normal and malignant human renal tissue: Relationship with progestin therapy

Enrico Ronchi, Giorgio Pizzocaro, Patrizia Miodini, Luigi Piva, Roberto Salvioni, Giovanni Di Fronzo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Documented hormone dependence of renal tumors in animal models, hypothetical hormonal environment of human kidney neoplasms and their controversial response to endocrine therapy prompted us to undertake a prospective multicentric cooperative study to evaluate the hormone-dependence/responsiveness of renal tumors. Patients with renal carcinoma were stratified accorcling to the TNM classification and after nephrectomy were treated with high-dose medroxyprogesterone acetate (MPA). Specimens of tumor and healthy surrounding kidney tissue were studied for titration of steroid receptor proteins (78 for androgen, AR, 89 for estrogen, ER, and progestin, PgR). Their true receptor nature was estimated. Very low titers (on an average <10 fmol/mg protein) were found, especially for ER and PgR in neoplastic samples. Occurrence rate of AR was low for both tissues (<20%), whereas ER and PgR were detected at a higher frequency in healthy parenchyma than in tumor tissue (42.2 vs 23.3% and 30.7 vs 11.2%, respectively). AR was moderately affected by metastatic status of the disease and by sex. All three steroid receptors were simultaneously detected in normal tissue in 11.7% of cases and in tumor tissue in only 3.8%. No significant correlation between receptor status in the tumor and clinical response to hormone therapy was found. In 27 cases who received adjuvant MPA therapy, relapses were respectively 43.8 and 18.2% in the patients with negative receptors or with at least one detectable receptor. In metastatic renal carcinoma, stabilization of the disease with MPA was achieved more frequently in receptor-negative patients. Therefore, we conclude that the receptor assay is not a valid tool to select renal carcinoma patients for therapy with MPA.

Original languageEnglish
Pages (from-to)329-335
Number of pages7
JournalJournal of Steroid Biochemistry
Volume21
Issue number3
DOIs
Publication statusPublished - 1984

Fingerprint

Steroid hormones
Steroid Receptors
Progestins
Tumors
Medroxyprogesterone Acetate
Hormones
Tissue
Kidney
Neoplasms
Carcinoma
Therapeutics
Neoplasm Staging
Kidney Neoplasms
Nephrectomy
Titration
Androgens
Assays
Estrogens
Animals
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Steroid hormone receptors in normal and malignant human renal tissue : Relationship with progestin therapy. / Ronchi, Enrico; Pizzocaro, Giorgio; Miodini, Patrizia; Piva, Luigi; Salvioni, Roberto; Di Fronzo, Giovanni.

In: Journal of Steroid Biochemistry, Vol. 21, No. 3, 1984, p. 329-335.

Research output: Contribution to journalArticle

Ronchi, Enrico ; Pizzocaro, Giorgio ; Miodini, Patrizia ; Piva, Luigi ; Salvioni, Roberto ; Di Fronzo, Giovanni. / Steroid hormone receptors in normal and malignant human renal tissue : Relationship with progestin therapy. In: Journal of Steroid Biochemistry. 1984 ; Vol. 21, No. 3. pp. 329-335.
@article{5cf7130dfe8c45699c6a123b3bbd0c83,
title = "Steroid hormone receptors in normal and malignant human renal tissue: Relationship with progestin therapy",
abstract = "Documented hormone dependence of renal tumors in animal models, hypothetical hormonal environment of human kidney neoplasms and their controversial response to endocrine therapy prompted us to undertake a prospective multicentric cooperative study to evaluate the hormone-dependence/responsiveness of renal tumors. Patients with renal carcinoma were stratified accorcling to the TNM classification and after nephrectomy were treated with high-dose medroxyprogesterone acetate (MPA). Specimens of tumor and healthy surrounding kidney tissue were studied for titration of steroid receptor proteins (78 for androgen, AR, 89 for estrogen, ER, and progestin, PgR). Their true receptor nature was estimated. Very low titers (on an average <10 fmol/mg protein) were found, especially for ER and PgR in neoplastic samples. Occurrence rate of AR was low for both tissues (<20{\%}), whereas ER and PgR were detected at a higher frequency in healthy parenchyma than in tumor tissue (42.2 vs 23.3{\%} and 30.7 vs 11.2{\%}, respectively). AR was moderately affected by metastatic status of the disease and by sex. All three steroid receptors were simultaneously detected in normal tissue in 11.7{\%} of cases and in tumor tissue in only 3.8{\%}. No significant correlation between receptor status in the tumor and clinical response to hormone therapy was found. In 27 cases who received adjuvant MPA therapy, relapses were respectively 43.8 and 18.2{\%} in the patients with negative receptors or with at least one detectable receptor. In metastatic renal carcinoma, stabilization of the disease with MPA was achieved more frequently in receptor-negative patients. Therefore, we conclude that the receptor assay is not a valid tool to select renal carcinoma patients for therapy with MPA.",
author = "Enrico Ronchi and Giorgio Pizzocaro and Patrizia Miodini and Luigi Piva and Roberto Salvioni and {Di Fronzo}, Giovanni",
year = "1984",
doi = "10.1016/0022-4731(84)90287-5",
language = "English",
volume = "21",
pages = "329--335",
journal = "Journal of Steroid Biochemistry",
issn = "0022-4731",
publisher = "Pergamon Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Steroid hormone receptors in normal and malignant human renal tissue

T2 - Relationship with progestin therapy

AU - Ronchi, Enrico

AU - Pizzocaro, Giorgio

AU - Miodini, Patrizia

AU - Piva, Luigi

AU - Salvioni, Roberto

AU - Di Fronzo, Giovanni

PY - 1984

Y1 - 1984

N2 - Documented hormone dependence of renal tumors in animal models, hypothetical hormonal environment of human kidney neoplasms and their controversial response to endocrine therapy prompted us to undertake a prospective multicentric cooperative study to evaluate the hormone-dependence/responsiveness of renal tumors. Patients with renal carcinoma were stratified accorcling to the TNM classification and after nephrectomy were treated with high-dose medroxyprogesterone acetate (MPA). Specimens of tumor and healthy surrounding kidney tissue were studied for titration of steroid receptor proteins (78 for androgen, AR, 89 for estrogen, ER, and progestin, PgR). Their true receptor nature was estimated. Very low titers (on an average <10 fmol/mg protein) were found, especially for ER and PgR in neoplastic samples. Occurrence rate of AR was low for both tissues (<20%), whereas ER and PgR were detected at a higher frequency in healthy parenchyma than in tumor tissue (42.2 vs 23.3% and 30.7 vs 11.2%, respectively). AR was moderately affected by metastatic status of the disease and by sex. All three steroid receptors were simultaneously detected in normal tissue in 11.7% of cases and in tumor tissue in only 3.8%. No significant correlation between receptor status in the tumor and clinical response to hormone therapy was found. In 27 cases who received adjuvant MPA therapy, relapses were respectively 43.8 and 18.2% in the patients with negative receptors or with at least one detectable receptor. In metastatic renal carcinoma, stabilization of the disease with MPA was achieved more frequently in receptor-negative patients. Therefore, we conclude that the receptor assay is not a valid tool to select renal carcinoma patients for therapy with MPA.

AB - Documented hormone dependence of renal tumors in animal models, hypothetical hormonal environment of human kidney neoplasms and their controversial response to endocrine therapy prompted us to undertake a prospective multicentric cooperative study to evaluate the hormone-dependence/responsiveness of renal tumors. Patients with renal carcinoma were stratified accorcling to the TNM classification and after nephrectomy were treated with high-dose medroxyprogesterone acetate (MPA). Specimens of tumor and healthy surrounding kidney tissue were studied for titration of steroid receptor proteins (78 for androgen, AR, 89 for estrogen, ER, and progestin, PgR). Their true receptor nature was estimated. Very low titers (on an average <10 fmol/mg protein) were found, especially for ER and PgR in neoplastic samples. Occurrence rate of AR was low for both tissues (<20%), whereas ER and PgR were detected at a higher frequency in healthy parenchyma than in tumor tissue (42.2 vs 23.3% and 30.7 vs 11.2%, respectively). AR was moderately affected by metastatic status of the disease and by sex. All three steroid receptors were simultaneously detected in normal tissue in 11.7% of cases and in tumor tissue in only 3.8%. No significant correlation between receptor status in the tumor and clinical response to hormone therapy was found. In 27 cases who received adjuvant MPA therapy, relapses were respectively 43.8 and 18.2% in the patients with negative receptors or with at least one detectable receptor. In metastatic renal carcinoma, stabilization of the disease with MPA was achieved more frequently in receptor-negative patients. Therefore, we conclude that the receptor assay is not a valid tool to select renal carcinoma patients for therapy with MPA.

UR - http://www.scopus.com/inward/record.url?scp=0021705388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021705388&partnerID=8YFLogxK

U2 - 10.1016/0022-4731(84)90287-5

DO - 10.1016/0022-4731(84)90287-5

M3 - Article

C2 - 6238209

AN - SCOPUS:0021705388

VL - 21

SP - 329

EP - 335

JO - Journal of Steroid Biochemistry

JF - Journal of Steroid Biochemistry

SN - 0022-4731

IS - 3

ER -